Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
IL-33 acts as a costimulatory signal to generate alloreactive Th1 cells in graft-versus-host disease
Gaelen K. Dwyer, Lisa R. Mathews, José A. Villegas, Anna Lucas, Anne Gonzalez de Peredo, Bruce R. Blazar, Jean-Philippe Girard, Amanda C. Poholek, Sanjiv A. Luther, Warren Shlomchik, Hēth R. Turnquist
Gaelen K. Dwyer, Lisa R. Mathews, José A. Villegas, Anna Lucas, Anne Gonzalez de Peredo, Bruce R. Blazar, Jean-Philippe Girard, Amanda C. Poholek, Sanjiv A. Luther, Warren Shlomchik, Hēth R. Turnquist
View: Text | PDF
Research Article Immunology

IL-33 acts as a costimulatory signal to generate alloreactive Th1 cells in graft-versus-host disease

  • Text
  • PDF
Abstract

Antigen-presenting cells (APCs) integrate signals emanating from local pathology and program appropriate T cell responses. In allogeneic hematopoietic stem cell transplantation (alloHCT), recipient conditioning releases damage-associated molecular patterns (DAMPs) that generate proinflammatory APCs that secrete IL-12, which is a driver of donor Th1 responses, causing graft-versus-host disease (GVHD). Nevertheless, other mechanisms exist to initiate alloreactive T cell responses, as recipients with disrupted DAMP signaling or lacking IL-12 develop GVHD. We established that tissue damage signals are perceived directly by donor CD4+ T cells and promoted T cell expansion and differentiation. Specifically, the fibroblastic reticular cell–derived DAMP IL-33 is increased by recipient conditioning and is critical for the initial activation, proliferation, and differentiation of alloreactive Th1 cells. IL-33 stimulation of CD4+ T cells was not required for lymphopenia-induced expansion, however. IL-33 promoted IL-12–independent expression of Tbet and generation of Th1 cells that infiltrated GVHD target tissues. Mechanistically, IL-33 augmented CD4+ T cell TCR-associated signaling pathways in response to alloantigen. This enhanced T cell expansion and Th1 polarization, but inhibited the expression of regulatory molecules such as IL-10 and Foxp3. These data establish an unappreciated role for IL-33 as a costimulatory signal for donor Th1 generation after alloHCT.

Authors

Gaelen K. Dwyer, Lisa R. Mathews, José A. Villegas, Anna Lucas, Anne Gonzalez de Peredo, Bruce R. Blazar, Jean-Philippe Girard, Amanda C. Poholek, Sanjiv A. Luther, Warren Shlomchik, Hēth R. Turnquist

×

Figure 2

IL-33 stimulation after alloHCT expands ST2+/+ CD4+ donor T cells and contributes to GVHD lethality independently of IL-12.

Options: View larger image (or click on image) Download as PowerPoint
IL-33 stimulation after alloHCT expands ST2+/+ CD4+ donor T cells and co...
(A–G) On d–1, BALB/c recipient mice (A–F) received α–IL-12p40 or IgG as control (as in Figure 1) and received lethal TBI. On d0, mice received 1 × 107 B6 TCD-BM with 2 × 106 CD90.2+ B6 St2–/– (ST2KO) or CD90.1+St2+/+ (ST2WT) CD3+T cells. Total splenocytes were assessed at d7 by flow cytometry. (A) Model schematic. (B) Representative ST2 expression on donor CD4+CD90.1+H2-Kd– ST2WT (red) and CD4+CD90.1–H2-Kd– ST2KO (blue) cells from recipient’s spleens at d7. (C) Frequency of ST2+ donor CD90.1–ST2KO and CD90.1+ST2WT CD4+ T cells. (D) Donor CD90.1–ST2KO and CD90.1+ST2WT CD4+ T cells counts in recipients that received α–IL-12p40 or IgG. (E) Representative CD44 expression on CD90.1–ST2KO (blue) and CD90.1+ST2WT (red) CD4+ T cells and quantification of CD44 MFI. (F) Representative Tbet expression on CD90.1–ST2KO (blue) and CD90.1+ST2WT (red) CD4+ T cells and quantification of Tbet MFI. (G) Survival graph depicting the influence of donor T cell ST2 deletion alone or with IL-12 neutralization on GVHD lethality. Data in B–F are represented as mean ± SD. Kaplan-Meier survival curve was used for G. n = 6–8/group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, 1-way ANOVA (C–F).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts